NEW YORK (TheStreet) -- Bristol-Myers Squibb (BMY) stock closed lower by 1.56% to $61.71 in Wednesday's trading session, ahead of the company's 2015 fourth quarter financial results, which are due out before tomorrow's market open.
Analysts are expecting the company to report a year-over-year decline in both earnings and revenue.
Analysts surveyed by Thomson Reuters have forecast for earnings of 28 cents per share on revenue of $4.14 billion for the quarter.
Last year, Bristol-Myers reoprted adjusted earnings of 46 cents per share on revenue of $4.26 billion for the fiscal 2014 fourth quarter.
Based in New York City, Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
Bristol-Myers Squibb's strengths such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance outweigh the fact that the company has had sub par growth in net income.
You can view the full analysis from the report here: BMY
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.